keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis c genotype 4

keyword
https://www.readbyqxmd.com/read/29792586/the-incubation-period-of-hepatitis-e-genotype-1-insights-from-pooled-analyses-of-travellers
#1
A S Azman, I Ciglenecki, C Oeser, B Said, R S Tedder, S Ijaz
Hepatitis E virus genotype 1 (HEV G1) is an important cause of morbidity and mortality in Africa and Asia. HEV G1's natural history, including the incubation period, remains poorly understood, hindering surveillance efforts and effective control. Using individual-level data from 85 travel-related HEV G1 cases in England and Wales, we estimate the incubation period distribution using survival analysis methods, which allow for appropriate inference when only time ranges, rather than exact times are known for the exposure to HEV and symptom onset...
May 24, 2018: Epidemiology and Infection
https://www.readbyqxmd.com/read/29792020/daclatasvir-and-asunaprevir-combination-therapy-for-patients-with-chronic-hepatitis-c-virus-genotype-1b-infection-in-real-world
#2
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
Background/Aims: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients with chronic hepatitis C virus (HCV) genotype 1b infection in real world. Methods: We enrolled 278 patients (184 treatment-naïve patients) from five hospitals in Daegu and Gyeongsangbuk-do...
May 25, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29783912/utilizing-clinical-pharmacist-specialist-to-manage-hepatitis-c-virus-patients-on-direct-acting-antiviral-therapy
#3
Lena A Mikolas, Kimberly Jacques, Mostaqul Huq, Charles Krasner, Scott E Mambourg
OBJECTIVES: To evaluate outcomes of a clinical pharmacist specialist (CPS)-managed hepatitis C virus (HCV) treatment clinic (HCVTC) in treating HCV-infected veterans with direct-acting antivirals (DAAs). METHODS: We established a CPS-managed HCVTC under a collaborative practice agreement with our infectious disease physician (IDP). A total of 132 veterans were treated between November 1, 2014, and November 30, 2015. The CPS engaged in pretreatment screening, drug selection, patient education, medication counseling, drug therapy monitoring, drug utilization review, addressing issues on drug adherence, and routine and posttreatment follow-up of patients to assess sustained virologic response (SVR) after 12 weeks of treatment...
January 1, 2018: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/29771105/direct-acting-antiviral-agents-in-patients-with-hepatitis-c-genotype-1-4-infections-in-a-tertiary-hospital
#4
J C Del Rio-Valencia, R Asensi-Diez, L Villalobos-Torres, I Muñoz Castillo
OBJECTIVE: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Six different genotypes (GT) of HCV (genotypes 1-6) have been identified. The genotype is clinically relevant since the majority of current direct antiviral agents (DAA´s) do not have pangenotypic efficacy. The purpose of this study was to describe the clinical characteristics of real world patients and evaluate the effectiveness of different treatment regimens. METHODS: Retrospective and observational study carried out in a third level hospital...
May 16, 2018: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://www.readbyqxmd.com/read/29768686/prevalence-and-predictive-factors-of-moderate-severe-liver-steatosis-in-chronic-hepatitis-c-chc-infected-patients-evaluated-with-controlled-attenuation-parameter-cap
#5
Ana Carolina Cardoso, Renata M Perez, Claudio de Figueiredo-Mendes, Nathalie Carvalho Leite, Henrique Sergio Moraes Coelho, Cristiane A Villela-Nogueira
A novel controlled attenuation parameter (CAP) using FibroScan® has been developed for assessment of liver steatosis. The aim was to evaluate the frequency and associated factors for moderate/severe steatosis evaluated by CAP in CHC patients submitted to transient elastography (TE) by FibroScan® . CHC patients underwent TE with CAP evaluation. The classification of steatosis was defined as: CAP < 222 dB/m = S0; CAP ≥ 222 dB/m and <233dB /m = S1; ≥233 dB/m <290dB/m = S2 and >= 290 dB/m = S3...
May 16, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29768546/first-wave-protease-inhibitors-for-hepatitis-c-genotype-1-treatment-a-real-life-experience-in-brazilian-patients
#6
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli
INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center...
March 2018: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/29761174/elbasvir-grazoprevir-in-asia-pacific-russian-participants-with-chronic-hepatitis-c-virus-genotype-1-4-or-6-infection
#7
Jacob George, Eduard Burnevich, I-Shyan Sheen, Jeong Heo, Nguyen Van Kinh, Tawesak Tanwandee, Pin-Nan Cheng, Do Young Kim, Won Young Tak, Svetlana Kizhlo, Konstantin Zhdanov, Vasily Isakov, Liwen Liang, Pauline Lindore, Joy Ginanni, Bach-Yen Nguyen, Janice Wahl, Eliav Barr, Michael Robertson, Paul Ingravallo, Rohit Talwani
The prevalence of hepatitis C virus (HCV) infection in Asian countries is high. This study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV infection from Asia-Pacific countries and Russia. In this phase 3, randomized, placebo-controlled, double-blind study, treatment-naive participants with HCV genotype (GT) 1, 4, or 6 infection were randomized to EBR 50 mg/GZR 100 mg (immediate-treatment group [ITG]) or placebo (deferred-treatment group [DTG]) once daily for 12 weeks (Protocol PN-5172-067, NCT02251990)...
May 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29759421/prevalence-and-distribution-of-hepatitis-c-virus-genotypes-in-galicia-during-the-period-2000-2015
#8
Daniel Navarro-de la Cruz, Sonia Pérez-Castro, Matilde Trigo-Daporta, Antonio Aguilera-Guirao
INTRODUCTION: We present the largest study conducted in Galicia on the prevalence and distribution of HCV genotypes/subtypes. METHODS: Retrospective study collecting the total number of patients chronically infected by HCV between 2000.01.01 to 2015.12.31 in 3of the main health areas: Santiago, Pontevedra and Vigo. RESULTS: We collected a total of 4469 patients. The median age was 50 years (IQR 57-45), 72,3% were men, 0,4% were coinfected with another genotype, 20,6% were coinfected with HIV and 35...
May 11, 2018: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/29755792/sofosbuvir-plus-daclatasvir-in-treatment-of-chronic-hepatitis-c-genotype-4-infection-in-a-cohort-of-egyptian-patients-an-experiment-the-size-of-egyptian-village
#9
Ossama Ashraf Ahmed, Eslam Safwat, Mohamed Omar Khalifa, Ahmed I Elshafie, Mohamed Hassan Ahmed Fouad, Mohamed Magdy Salama, Gina Gamal Naguib, Mohamed Mahmoud Eltabbakh, Ahmed Fouad Sherief, Sherief Abd-Elsalam
Background and Aims: As indicated by the World Health Organization (WHO), Egypt is positioned as the country with the world's highest prevalence of Hepatitis C virus (HCV). HCV is transmitted through unexamined blood transfusions, different employments of syringes, and poor cleansing, as per the WHO. Our study aimed at screening and management of chronic hepatitis C genotype 4 infected patients in Bardeen village, Sharkeya Governorate, Egypt, with Sofosbuvir plus Daclatasvir, as well as estimating the safety and efficacy of that regimen...
2018: International Journal of Hepatology
https://www.readbyqxmd.com/read/29755014/diagnosis-of-cirrhosis-in-patients-with-chronic-hepatitis-c-genotype-4-role-of-abcb11-genotype-polymorphism-and-plasma-bile-acid-levels
#10
Tarek Besheer, Mona Arafa, Mohamed Abd El-Maksoud, Hatem Elalfy, Amany Hasson, Khaled Zalata, Wagdi Elkashef, Heba Elshahawy, Doaa Raafat, Wafaa Elemshaty, Eman Elsayed, Hosam Zaghloul, Ahmed Abdel Razek, Mahmoud El-Bendary
BACKGROUND/AIMS: Chronic hepatitis C (CHC)-related mortality generally results from cirrhosis and subsequent complications. We aimed to investigate the potential role of plasma bile acid levels and ABCB11 1331T > C (V444A, rs2287622) (ATP-binding cassette subfamily B, member 11) gene polymorphism in fibrosis prediction in CHC genotype 4 patients. MATERIALS AND METHODS: This case control study included 85 healthy control and the following 225 subjects: 170 adult patients infected with hepatitis C virus (HCV) and categorized into three groups according to liver biopsy; no fibrosis group (F0) (n=33), early fibrosis group (F1-F2) (n=61), and advanced fibrosis group (F3-F4) (n=76)...
May 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29754329/efficacy-and-safety-of-sofosbuvir-plus-daclatasvir-with-or-without-ribavirin-large-real-life-results-of-patients-with-chronic-hepatitis-c-genotype-4
#11
Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabaar, Mohamed I Zanaty, Mohamed Ramadan
BACKGROUND AND AIM: Clinical studies evaluating the efficacy of daclatasvir (DCV) for treatment of chronic hepatitis C virus (HCV) genotype 4 (GT4) infection are scarce. This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian patients infected with HCV GT4. METHODS: Between April 2016 and March of 2017, a large cohort of 946 patients with chronic HCV GT4 was enrolled for completing the treatment...
May 12, 2018: Hepatology International
https://www.readbyqxmd.com/read/29753376/effectiveness-of-sofosbuvir-ribavirin-and-peg-ifn%C3%AE-2a-in-the-treatment-of-na%C3%A3-ve-egyptian-patients-with-chronic-hepatitis-c-virus-genotype-4
#12
Fatma Abdallah, Gehad Mohamed, Mohsen Ibrahim, Mokhtar El Tarabily
BACKGROUND: Egypt is one of the largest epidemic areas of hepatitis C virus (HCV) in the world. Its prevalent genotype is 4 with a majority of subtype 4a. In 2013, the Food and Drug Administration approved a new direct-acting antiviral drug (sofosbuvir) to treat patients with chronic HCV infection. In Egypt, the patients are already being treated with sofosbuvir in conjunction with ribavirin and pegylated interferon alfa-2a (PEG-IFNα-2a) for 12 weeks since 2015. The present study was planned to explain the efficacy of this treatment regimen against the HCV genotype 4a in Egyptian patients and its pretreatment predictive factors of virological response...
May 2018: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/29750017/pharmacokinetic-characteristics-of-telaprevir-in-healthy-korean-male-subjects-and-comparisons-with-japanese
#13
Yewon Choi, Seonghae Yoon, Kyoko Matsumoto, Yoshiyasu Ohta, SeungHwan Lee, Kyung-Sang Yu, In-Jin Jang
Introduction: Telaprevir, a reversible selective inhibitor of viral protease and a potential blocker of viral replication, is indicated for the treatment of hepatitis C virus genotype 1 infection. In this study, the pharmacokinetic profile, safety, and tolerability of telaprevir and the effect of food on telaprevir exposure were evaluated in healthy Korean subjects, and compared with data from a previous study in Japanese male subjects. Methods: The single ascending dose study was conducted in 3 dose-based groups (500, 750, and 1,250 mg, six subjects each) in a fasted state...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29746724/efficacy-and-safety-of-elbasvir-grazoprevir-fixed-dose-in-the-management-of-polytreated-hcv-patients-evidence-from-real-life-clinical-practice
#14
Benedetto Caroleo, Lidia Colangelo, Maria Perticone, Giovambattista De Sarro, Luca Gallelli
Chronic hepatitis C virus (HCV) infection represents a global public health challenge, and new drugs have been authorized for its treatment. In this study, we evaluated both the clinical efficacy and safety of elbasvir-grazoprevir fixed-dose combination in HCV patients. We performed a prospective single-blind study on patients admitted to the Regional Center for HCV Treatment of the University of Catanzaro from March 1, 2017, to December 31, 2017, in patients >30 years old with a history of chronic HCV infection...
May 10, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29745936/worldwide-prevalence-of-baseline-resistance-associated-polymorphisms-and-resistance-mutations-in-hcv-against-current-direct-acting-antivirals
#15
Navaneethan Palanisamy, Prabhav Kalaghatgi, Dario Akaberi, Åke Lundkvist, Zhi-Wei Chen, Peng Hu, Johan Lennerstrand
BACKGROUND: Hepatitis C virus (HCV) infections can now be completely cured, thanks to the currently marketed direct-acting antivirals (DAAs). It is known that HCV patients carry viral populations with baseline polymorphisms and/or mutations that make them resistant against some of these DAAs, which can negatively impact the patient's treatment outcome. Using complete HCV coding sequences isolated from 1306 treatment-naïve patients of genotypes (GTs) 1, 2, 3, 4 and 6 from around the globe, we studied the prevalence of baseline resistance-associated polymorphisms (RAPs) and resistance mutations (RMs) against DAAs that are currently on the market or in clinical trials...
May 10, 2018: Antiviral Therapy
https://www.readbyqxmd.com/read/29745758/evaluation-of-heating-conditions-for-inactivation-of-hepatitis-e-virus-genotypes-3-and-4
#16
Toshifumi Imagawa, Ryuichi Sugiyama, Tomoyuki Shiota, Tian-Cheng Li, Sayaka Yoshizaki, Takaji Wakita, Koji Ishii
Hepatitis E virus (HEV) is a causative agent of acute hepatitis throughout the world. HEV genotypes 1 through 4 infect humans, whereas genotypes 3 and 4 (Gt3 and Gt4) also infect other animals. In developed countries, the main HEV infection route is by foodborne transmission, resulting from the consumption of undercooked meat. It is important to know the criteria for HEV control in daily cooking. In this study, we assessed the heat conditions required to inactivate HEV Gt3 and Gt4 in culture supernatants and spiked minced pork meat...
May 10, 2018: Journal of Food Protection
https://www.readbyqxmd.com/read/29743792/effect-of-sofosbuvir-plus-daclatasvir-in-hepatitis-c-virus-genotype-4-patients-promising-effect-on-liver-fibrosis
#17
Asmaa M Abdel-Aziz, Mohamed A Ibrahim, Azza A El-Sheikh, Maha Y Kamel, Nagwa M Zenhom, Salam Abdel-Raheim, Hisham Abdelhaleem
Background/purpose: The effect of sofosbuvir and daclatasvir in treatment of genotype 4 Hepatitis C Virus (HCV) is not well documented. This study investigated the safety and efficacy of sofosbuvir plus daclatasvir with or without ribavirin in treatment of HCV genotype 4 patients. The impact of therapy on liver fibrosis as well as the role of IL18 polymorphism in therapeutic outcome was assessed. Methods: One hundred HCV genotype 4 patients were categorized into 2 groups...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29743791/impact-of-direct-acting-antiviral-therapy-for-treatment-of-hepatitis-c-genotypes-1-3-and-4-a-real-life-experience-from-india
#18
Varun Mehta, Ramit Mahajan, Vandana Midha, Vikram Narang, Kirandeep Kaur, Arshdeep Singh, Anand Malhotra, Aslam Parvez, Ajit Sood
Objective: To assess impact of Direct Acting Antiviral (DAA) therapies for treatment of Hepatitis C Virus (HCV) genotypes 1, 3 and 4 in a real-world cohort from India. Methods: Adults with chronic HCV infection treated with Sofosbuvir (SOF) and Ledipasvir (LDV) (genotypes 1 and 4) or SOF and Daclatasvir (DCV) (genotype 3), with or without Ribavirin (RBV) between December 2015 and December 2016 were included. The primary endpoint was Sustained Virological Response at Post-treatment Week 12 (SVR12)...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29743790/safety-and-efficacy-of-sofosbuvir-and-daclatasvir-for-hepatitis-c-virus-infection-in-patients-with-%C3%AE-thalassemia-major
#19
Rajiv Mehta, Mayank Kabrawala, Subhash Nandwani, Pankaj Desai, Vishwa Bhayani, Sanjay Patel, Viral Parekh
Background and Aims: β-thalassemia major patients are susceptible to Hepatitis C Virus (HCV) infection owing to life-long dependency for blood-transfusion. Moreover, this patient population is at risk of progression of liver fibrosis or development of cirrhosis as a consequence of both iron overload and HCV infection. Hence, this study was carried out to evaluate efficacy and safety of the combination regimen of sofosbuvir and daclatasvir for HCV infection in β-thalassemia major patients...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29743673/ancient-hepatitis-b-viruses-from-the-bronze-age-to-the-medieval-period
#20
Barbara Mühlemann, Terry C Jones, Peter de Barros Damgaard, Morten E Allentoft, Irina Shevnina, Andrey Logvin, Emma Usmanova, Irina P Panyushkina, Bazartseren Boldgiv, Tsevel Bazartseren, Kadicha Tashbaeva, Victor Merz, Nina Lau, Václav Smrčka, Dmitry Voyakin, Egor Kitov, Andrey Epimakhov, Dalia Pokutta, Magdolna Vicze, T Douglas Price, Vyacheslav Moiseyev, Anders J Hansen, Ludovic Orlando, Simon Rasmussen, Martin Sikora, Lasse Vinner, Albert D M E Osterhaus, Derek J Smith, Dieter Glebe, Ron A M Fouchier, Christian Drosten, Karl-Göran Sjögren, Kristian Kristiansen, Eske Willerslev
Hepatitis B virus (HBV) is a major cause of human hepatitis. There is considerable uncertainty about the timescale of its evolution and its association with humans. Here we present 12 full or partial ancient HBV genomes that are between approximately 0.8 and 4.5 thousand years old. The ancient sequences group either within or in a sister relationship with extant human or other ape HBV clades. Generally, the genome properties follow those of modern HBV. The root of the HBV tree is projected to between 8.6 and 20...
May 9, 2018: Nature
keyword
keyword
86765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"